BioAdaptives Signs Non-Exclusive License With LY Research to Market Patented Product for Glucose Management

Rhea-AI Summary

BioAdaptives, Inc. (OTCMkts: BDPT) has signed a non-exclusive license agreement with LY Research Corporation to market a patented glucose management product (Patent # US 8,114,444 B2), valued at $210 million. This partnership aims to capitalize on the growing diabetes supplement market, projected to reach $31.42 billion by 2030, with a CAGR of 10.3% from 2022-2030. The product, Glucobotanic, contains compounds that help regulate blood glucose levels and may inhibit sugar conversion to fat. BioAdaptives focuses on natural plant- and algal-based health products, currently serving over 13,000 shareholders.

Positive

• Signed a lucrative non-exclusive license agreement with LY Research Corporation.
• Patent for glucose management product valued at $210 million.
• Market potential highlighted by projected growth in the diabetes supplement sector.

Negative

• None.

LY Research Patent # US 8,114,444 B2 is Valued at US$210,000,000

LAS VEGAS, NV, March 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts:  BDPT) announced today the signing of a non-exclusive license agreement with LY Research Corporation to market a patented product (Patent # us 8,114,444 B2 ) for glucose management. 

Edward Jacobs, M.D.,CEO BioAdaptives, Inc., comments, “We are very excited to be working with Dr. Yaguang Liu, LY Research, in bringing this breakthrough glucose balance and glycemic wellness supplement to the market.  Dr. Liu is considered to be one of the world’s top botanical product experts. According to Statista, Around 10.5 percent of the global adult population suffered from diabetes in 2021 - by the year 2045 this number is expected to rise to over 12 percent. According to Straits Research, The Global Diabetes Supplement Market size was valued at 13.21 billion in 2021 and is expected to reach a valuation of USD 31.42 billion by 2030. The market is expected to grow at a CAGR of 10.3% during the forecast period (2022–2030).”

David Allen, PhD, CEO World Wellness, Inc. and President of the American Botanical Drug Association, who will be involved in this project, said, “Glucobotanic is a product developed and protected under US patent for lowering blood glucose. The patent has a valuation of US$210/m as valued by Grant Thornton Accounting Firm. It contains several biologically active compounds called bitters, including charantin and momordicin that help to maintain glucose health. It helps to inhibit the conversion of sugar into fat and stimulates the breakdown of fat in the body. In the United States, approximately 84 million adults—more than 1 out of 3—have prediabetes. Of those with prediabetes, 90% don't know they have it. When our blood sugar is balanced, we feel our best.”

About BioAdaptives, Inc.

BioAdaptives, Inc. manufactures and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, anti-viral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties.  The Company’s current dietary supplement formulations are carefully selected from the best world-wide sources and utilize proprietary methods of enhancing the bioavailability of nutrients.  The products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance.  Our current product line includes PrimiLungs™, PluriPain®, SleepEZ™, MindnMemory™ and Cell Rejuven™ for humans and Canine Regen All In One™, Equine All-in-One™ and Equine All In One Plus™ for dogs and horses.

BioAdaptives’ common shares trade in the OTC market under the symbol BDPT.  It has over 13,000 current shareholders.  None of the statements about the Company’s products have been approved by the Food and Drug Administration.  These products are not intended to diagnose, treat, cure, or prevent any disease.”

Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany

About LY Research Corporation

LY Research Corporation is a privately owned company founded by Dr. Yaguang Liu in New Jersey. The Company is mainly engaged in the development, manufacturing and marketing of botanical drug products and nutraceuticals in China, Europe, and the U.S. Within the past decade, LY Research and its owner, Dr. Liu has received 32 patents from the U. S. Patent and Trademark Office for safe natural botanicals, used for treatment of Alzheimer’s, Cardiovascular, Myopia and other conditions. Dr. Liu was born and educated in the People’s Republic of China. He graduated from Fudan University, Shanghai and had been a visiting Professor at the Department of Medicine of the University of Chicago. He established the Molecular Medicine Institute in China and was a director of this institute. He has authored four books: (1) An Investigation of the Combined Theories of Chinese and Western Medicines from the Angle of Molecular Biology; (2) Molecular Biology in Heart Disease; (3) Principles of Theoretical Medicine; and (4) Natural Science and the Theory of Chinese Medicine.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Contact:
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
info@bioadaptives.com

FAQ

What is the significance of the license agreement between BioAdaptives and LY Research for BDPT?

The license agreement allows BioAdaptives to market a patented glucose management product, potentially increasing revenue and market presence.

What is the estimated market value for the diabetes supplement industry?

The diabetes supplement market size is projected to reach $31.42 billion by 2030.

What is the patent number for the product BioAdaptives is licensing?

The patent number for the glucose management product is US 8,114,444 B2.

How many shareholders does BioAdaptives currently have?

BioAdaptives has over 13,000 current shareholders.